Tempest Therapeutics, Inc. (TPST)
NASDAQ: TPST · Real-Time Price · USD
0.898
+0.033 (3.85%)
Nov 20, 2024, 4:00 PM EST - Market closed
Tempest Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Selling, General & Admin | 13.71 | 11.66 | 12.11 | 9.82 | 4.91 | 5.51 |
| Research & Development | 21.92 | 17.5 | 22.53 | 17.17 | 14.39 | 17.87 |
| Operating Expenses | 35.62 | 29.16 | 34.64 | 26.99 | 19.3 | 23.37 |
| Operating Income | -35.62 | -29.16 | -34.64 | -26.99 | -19.3 | -23.37 |
| Interest Expense | -1.45 | -1.45 | -1.62 | -1.28 | - | - |
| Interest & Investment Income | 1.55 | 1.12 | 0.55 | - | 0.09 | 0.26 |
| Other Non Operating Income (Expenses) | - | - | - | -0.03 | - | 8.75 |
| Pretax Income | -35.52 | -29.49 | -35.71 | -28.3 | -19.21 | -14.36 |
| Income Tax Expense | - | - | - | - | - | 0 |
| Net Income | -35.52 | -29.49 | -35.71 | -28.3 | -19.21 | -14.37 |
| Net Income to Common | -35.52 | -29.49 | -35.71 | -28.3 | -19.21 | -14.37 |
| Shares Outstanding (Basic) | 23 | 15 | 12 | 4 | 0 | 1 |
| Shares Outstanding (Diluted) | 23 | 15 | 12 | 4 | 0 | 1 |
| Shares Change (YoY) | 61.11% | 33.49% | 204.70% | 709.62% | -44.17% | - |
| EPS (Basic) | -1.58 | -1.91 | -3.09 | -7.47 | -41.03 | -17.13 |
| EPS (Diluted) | -1.58 | -1.91 | -3.09 | -7.47 | -41.03 | -17.13 |
| Free Cash Flow | -29.49 | -27.53 | -31.63 | -26.09 | -19.07 | -22.92 |
| Free Cash Flow Per Share | -1.31 | -1.79 | -2.74 | -6.88 | -40.73 | -27.34 |
| EBITDA | -35.2 | -28.78 | -34 | -26.61 | -18.96 | -23.27 |
| D&A For EBITDA | 0.43 | 0.38 | 0.64 | 0.37 | 0.34 | 0.1 |
| EBIT | -35.62 | -29.16 | -34.64 | -26.99 | -19.3 | -23.37 |
Source: S&P Capital IQ. Standard template.
Financial Sources.